Trademark: 85674444
Word
AIMPHARMA
Status Date
Friday, June 19, 2020
Registration Number
4433507
Registration Date
Tuesday, November 12, 2013
Filing Date
Wednesday, July 11, 2012
Published for Opposition
Tuesday, January 1, 2013
Cancellation Date
Friday, June 19, 2020
5 Adjuvants for medical purposes; adrenal hormone preparations; anesthetics for surgical and non-surgical use; analgesic preparations; analgesics; androgen preparations; anti-allergic medicines; antibacterial substances for medical purposes; antibiotic preparations; antibiotics; anticoagulants; antidepressants; anti-diabetic preparations; antidotes; antiemetics; antifungal creams for medical use; antifungal preparations; antihypertensives; antimicrobials for dermatologic use; antiseptic preparations; antitoxic sera; anti-cancer preparations; anti-cough drops; anti-dermoinfectives; anti-infective products for veterinary use; anti-inflammatory and antipyretic preparations; anti-sarcoma preparations; anti-uric preparations; appetite suppressants; bacterial and bacteriological preparations for medical or veterinary purposes; biological preparations for the treatment of cancer; chemical reagents for medical or veterinary purposes; chemotherapeutics; composite materials for dental and dental technical purposes; diagnostic preparations for medical purposes; diagnostic reagents for medicinal use; ferments for medical or veterinary use; fungicides for medical use; gases and gas mixtures for medical imaging use; gastrointestinal cleaning agents; gels, creams and solutions for dermatological use; general anesthetics; glucose for medical purposes; hormones for medical purposes; inhalant anesthetics; inhaled pharmaceutical preparations for the treatment of respiratory diseases and disorders; insulin; Intravenous fluids used for rehydration, nutrition and the delivery of pharmaceutical preparations; lipotropic factor preparations; local anesthetics; medicinal herbal extracts for medical purposes; medicines for the treatment of gastrointestinal diseases; milk ferments for pharmaceutical purposes; nutritive substances for micro-organisms for medical use; ophthalmic preparations; ophthalmologic preparations; oral vaccine preparations; pancreas hormone preparations; penicillin preparations; pharmaceutical anti-allergic preparations and substances; pharmaceutical for the treatment of erectile dysfunction; pharmaceutical preparations acting on the central nervous system; pharmaceutical preparations and substances for the treatment of gastro-intestinal diseases; pharmaceutical preparations for animal skincare; pharmaceutical preparations for inhalation for the treatment of pulmonary hypertension; pharmaceutical preparations for ocular or intraocular surgery; pharmaceutical preparations for the treatment of hormonal disorders and the prevention of osteoporosis; pharmaceutical preparations for treating allergic rhinitis and asthma; pharmaceutical preparations for treating diabetes; pharmaceutical preparations for treating skin disorders; pharmaceutical preparations for use in dermatology; pharmaceutical preparations for wounds; pharmaceutical preparations for skin care; pharmaceutical preparations for treating allergies; pharmaceutical preparations for treating hypertension; pharmaceutical products and preparations for preventing skin blemishes during pregnancy; pharmaceutical products for the treatment of bone diseases; pharmaceutical products for the treatment of viral and infectious diseases, for the treatment of cancer; pharmaceutical products for treating respiratory diseases and asthma; pharmaceutical products for the prevention and treatment of cancer; pharmaceutical solutions used in dialysis; pharmaceuticals for the treatment of erectile dysfunction; pheromones for medical use; pituitary hormone preparations; preparations for detecting genetic predispositions for medical purposes; preparations for detecting mutation in prion genes for medical purposes; preparations for the treatment of asthma; radio-isotope markers for therapeutic or diagnostic use; reagents and media for medical and veterinary diagnostic purposes; reagents for medical use; stem cells for medical purposes; surgical tissues; tetracycline preparations; thyroid and para-thyroid hormone preparations; topical analgesic creams; trichomycin preparations; tumor suppressing agents; vaccine preparations; vaccines for cattle; vasoconstrictors; veterinary preparations for treatment of intestinal bacteria; virucides; yeast or yeast extracts for medical, veterinary or pharmaceutical purposes
The color(s) blue and grey is/are claimed as a feature of the mark.
The mark consists of two oval pill shaped designs forming a stylized cross with the vertical pill design appearing in blue overlaying the horizontal pill design appearing in grey next to the words "AimPharma" with "Aim" appearing in blue and "Pharma" appearing in grey.
AIM PHARMACY
Jun 19, 2020
Cancelled Sec. 8 (6-Yr)
Nov 12, 2018
Courtesy Reminder - Sec. 8 (6-Yr) E-Mailed
Nov 12, 2013
Registered-Principal Register
Oct 9, 2013
Notice Of Acceptance Of Statement Of Use E-Mailed
Oct 8, 2013
Law Office Registration Review Completed
Sep 30, 2013
Allowed Principal Register - Sou Accepted
Sep 27, 2013
Statement Of Use Processing Complete
Aug 16, 2013
Use Amendment Filed
Sep 13, 2013
Case Assigned To Intent To Use Paralegal
Aug 16, 2013
Teas Statement Of Use Received
Feb 26, 2013
Noa E-Mailed - Sou Required From Applicant
Jan 1, 2013
Official Gazette Publication Confirmation E-Mailed
Jan 1, 2013
Published For Opposition
Dec 12, 2012
Notification Of Notice Of Publication E-Mailed
Nov 26, 2012
Law Office Publication Review Completed
Nov 26, 2012
Assigned To Lie
Nov 6, 2012
Approved For Pub - Principal Register
Nov 6, 2012
Examiner's Amendment Entered
Nov 6, 2012
Notification Of Examiners Amendment E-Mailed
Nov 6, 2012
Examiners Amendment E-Mailed
Nov 6, 2012
Examiners Amendment -Written
Nov 1, 2012
Assigned To Examiner
Jul 19, 2012
Notice Of Design Search Code Mailed
Jul 18, 2012
New Application Office Supplied Data Entered In Tram
Jul 14, 2012
New Application Entered In Tram
Trademark Alertz updated from USPTO on 2030-01-24
